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OBJECTIVES We prospectively studied the relationship between left ventricular (LV) dilation, dysfunction,
electrical instability and death in patients after a first myocardial infarction (MI) without
symptoms of heart failure and ischemia.
BACKGROUND Mechanisms linking LV dysfunction and sudden death in patients after MI remained
controversial.
METHODS Left ventricular volumes, hemodynamics, electrocardiogram and 24-h Holter recordings were
sequentially obtained between two days and seven years after MI. Left ventricular catheter-
ization and coronary angiography were performed, and revascularization was performed if
appropriate.
RESULTS Death occurred in 16 (12%) of the 134 patients included; it was of cardiac origin in 14 (88%)
and sudden in origin in 12 (75%) patients. Of 37 (28%) patients with LV dilation, 12 died
(32%); four patients (5.8%) died in the group without dilation. Left ventricular dilation was
closely related to signs of electrical instability, as indicated by a significant correlation between
end-diastolic LV volume index, Lown score (r 5 0.98, p , 0.0001) and QTc prolongation
(r 5 0.998, p , 0.01), respectively.
CONCLUSIONS Patients with progressive remodeling are at increased risk of sudden death in chronic MI.
Cardiac electrical instability is closely related to progressive LV dilation. Parameters of
electrical instability and remodeling are predictors of sudden death. The findings suggest that
remodeling might serve as a link between dysfunction, electrical instability of the heart and
sudden death after MI. (J Am Coll Cardiol 2001;38:33–40) © 2001 by the American
College of Cardiology
Patients with heart failure are at high risk for sudden death
(1,2). The relationship between the degree of dysfunction,
occurrence of ventricular arrhythmias and the risk of sudden
death (2,3) and the mechanism leading from dysfunction to
sudden death are not clear. Identification of patients with
left ventricular (LV) dysfunction who are at increased risk
for sudden death and the potential influence of therapy on
these patients is difficult to assess. Ejection fraction has low
specificity (4); predictors of electrical instability are limited
by a high false-positive rate and a positive predictive value of
,30% (5–7). It is controversial whether or not sudden death
and severity of heart failure are directly related (4,8–10)
since their occurrence is not temporally related, and patients
with less severe heart failure had a greater risk of sudden
death in the Vasodilator-Heart Failure Trial (V-HeFT)
patient population (11). Left ventricular volume, as a
hallmark of the remodeling process (12), is one of the most
powerful predictors of long-term survival in patients after
myocardial infarction (MI) (13) and contributes to progres-
sive dysfunction (14,15). This prospective study, which was
conducted in patients who were asymptomatic after MI, was
designed to analyze the process leading from dysfunction to
death in individual patients. We tested the hypothesis that
progressive LV dilation is closely related to electrical insta-
bility and may serve as a link between dysfunction and
death.
METHODS
Patient selection. From January 1987 to January 1990, 416
patients were admitted to our intensive care unit with acute
MI confirmed by electrocardiogram (ECG) and creatine
kinase enzymes. Thrombolytic therapy was administered if
not contraindicated according to currently accepted criteria.
Of these patients, 175 matched our inclusion criteria (age of
#70 years, first MI and signed informed consent). Patients
were excluded with clinical signs of heart failure or cardio-
genic shock in the first week after MI, unstable angina,
life-limiting noncardiac disease, conditions precluding car-
diac catheterization or exercise testing or delayed (.6 days)
hospital admission. Twenty-four patients refused to partic-
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ipate, and an additional 17 patients were excluded who did
not adhere to the follow-up protocol.
Study protocol. The protocol was approved by the Insti-
tutional Committee on Human Experimentation and in
accordance with the Helsinki Declaration. Four days (two
to six days), four weeks (three to five weeks), six months
(five to eight months), 1.5 years (16 to 20 months) and three
to seven years (58 to 86 months) after admission, 12-lead
ECGs and 24-h Holter were obtained. Additionally, LV
end-diastolic and end-systolic volumes and ejection fraction
were measured, and right heart catheterization was performed
simultaneously at rest. Four weeks after admission, coronary
angiography and biplane cineangiography were performed in
all patients. Patients were fasting the night before and were off
medication for the previous 24 h. The patients’ therapy
remained the responsibility of the attending physician.
LV volumes and ejection fraction. Gated blood pool
radionuclide ventriculograms were sequentially obtained in
each patient as described in detail elsewhere (15). In brief,
erythrocytes were labeled “in vivo” by 15 to 20 mCi
technetium-99m pertechnetate. The cardiac cycle was gated
into eight frames triggered by ECG and images obtained by
a rotating gamma camera (gated single photon emission
computed tomography) followed by standard planar radio-
nuclide ventriculography for determination of global LV
ejection fraction.
Hemodynamics and angiography. Coronary angiography
in multiple views and biplane LV angiography were per-
formed by a Sones procedure. Infarct size was quantitated as
the percentage of akinetic and dyskinetic segment length of
the total end-diastolic circumference of the biplane contrast
LV angiogram (15). Perfusion of infarct-related coronary
artery was assessed according to the Thrombolysis In
Myocardial Infarction (TIMI) trial (16). An operator
blinded to the other measurements performed these mea-
surements. Right heart catheterization was performed and
cardiac output measured by a Swan-Ganz thermodilution
catheter (7F Edwards, Braun-Melsungen AG, Melsungen,
Germany) and a Siemens Sirecust 404-1A (Erlanger, Ger-
many) computer by three repeated injections of 10.0 ml iced
saline. Left ventricular stroke volume was calculated and
related to body surface area as stroke volume index. For
right heart catheterizations performed separate from an-
giography, a transcutaneous (“Seldinger”) approach was
used.
Rhythm analysis. HOLTER ANALYSIS. Methods of Holter
recordings matched the guidelines of the American Heart
Association and European Society of Cardiology (17,18).
Automatic Holter analysis included 24-h heart rate variabil-
ity and average, maximum and minimum heart rate using
the ELA Medical System (Mu¨nchen, Germany). Correct-
ness of the automatic measurements was validated by
comparison of automatic with visual analysis of 10 randomly
selected 24-h recordings. Sensitivity and specificity of the
automatic measurements were 100% and 95%, respectively.
Arrhythmias were visually assigned and quantitated. Intra-
and interobserver variability was low, as indicated by posi-
tive correctness of 98%. Ventricular arrhythmias were cate-
gorized according to the modified Lown classification (19),
and each Lown grade was assigned to a score number from
zero to 7. Deviation of normal RR intervals (resulting from
sinus node depolarizations, standard deviation of the NN
interval [SDNN], ms, ELA Medical System) were deter-
mined after manual correction of automated analysis for
supraventricular and ventricular premature beats or artifacts,
respectively (18). Standard deviation of the averages of NN
intervals in all 5-min segments of the entire 24-h recording
(SDANN [ms]) was determined. Standard deviation of the
averages of NN intervals and SDANN were determined
following guidelines of the European Society of Cardiology
(18).
QT analysis. QT duration, as the interval from the
Q-wave deflection to the end of the T-wave, was measured
in high quality 24-lead surface ECG recordings. The final
value is the average of three measurements in each of the 12
leads. These measurements were corrected for heart rate
(RR interval) and expressed as QTc using the equation:
QTc 5 QT/RR20.5 (20). A QTc duration .0.45 s was
considered to be prolonged (5). To assess dispersion of QTc
duration within the 12-lead ECG, the difference between
the largest and smallest QTc duration was calculated on-
line after digitization of original ECG tracings using a
calibrated digitizing tablet (Numonics, Montgomeryville,
Pennsylvania) and the Sigma Scan Pro (SPSS ASC GmbH,
Erkrath, Germany) software package by a person blinded to
all other data.
Analysis of deaths. The dates of all deaths were docu-
mented, and details of the events at the time of death and
the preterminal conditions of the patient were obtained
from family members, friends or the treating physician.
Sudden death without prodromes was defined according to
the currently accepted criteria as death that occurred within
1 h of the onset of acute symptoms. It was assumed to be
cardiac if no other explanations were found. Sudden death
with prodromes was defined accordingly if symptoms such
as new or worsening chest pain, palpitations, dyspnea or
weakness occurred within 24 h before death.
Laboratory measurements. Thirty minutes after place-
ment of a venous line between 10 AM and 2 PM and supine
rest, blood samples were drawn for standard laboratory tests.
Additional blood was collected into prechilled tubes, cen-
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
BUN 5 blood urea nitrogen
ECG 5 electrocardiogram
LV 5 left ventricle/ventricular
MI 5 myocardial infarction
SDANN 5 standard deviation of the average NN
interval
SDNN 5 standard deviation of the NN interval
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trifuged at 4°C at 2,500 rpm for 12 min and plasma stored
in a polypropylene tube at 220°C for renin activity, atrial
natriuretic peptide (ANP) and catecholamines measure-
ments. Plasma catecholamines were measured by high-
pressure liquid chromatography. Plasma renin activity and
ANP were measured by radioimmunoassay using commer-
cially available antibodies.
Statistical analysis. Clinical characteristics at baseline (Ta-
ble 1) and the last visit (Table 2) between survivors and
nonsurvivors were compared by Student t test. Two-way
analysis of variance was performed to test for differences
over time and between survivors and nonsurvivors. The
survival curves were compared by the log-rank test. Age,
ventriculographic MI size, percent narrowing of MI-related
artery, ejection fraction, stroke volume index, LV end-
diastolic and end-systolic volume index, mean pulmonary
capillary wedge pressure, mean right atrial pressure, maxi-
mum, minimum and mean heart rate (Holter), Lown score,
QTc dispersion, maximum QTc duration, serum creatinine,
blood urea nitrogen (BUN), plasma ANP and a discrimi-
nate score “discscore” were preselected to have independent
effects on survival. “Discscore” was derived from multivari-
ate discriminant analysis in a previous publication (15) from
the following: ejection fraction on day 4, ventriculographic
MI size, MI location, stroke index at day 4 and the rate of
arteriographic contrast flow in the MI artery (TIMI grade).
These variables were significant predictors of progressive,
limited or no LV dilation and classified 89% of the patients
correctly. Using the discriminant coefficients, a “risk equa-
tion” can be provided (15). The contribution of the disc-
score and other covariates was investigated by stepwise
logistic regression (21). This was achieved by a standard
approach for multivariate analysis using stepwise automatic
logistic regression (SAS software package 6.12; SAS Insti-
tute, Cary, North Carolina). For the multivariate procedure,
variables were used only if they showed a p value ,0.05 in
univariate analysis. A value of p ,0.05 indicated a signifi-
cant difference. Results are presented as mean 6SEM.
RESULTS
Survival curves. Of 134 patients, 16 (12%) died. Deaths
were considered cardiac in 14 (88%) patients, sudden
without preceding symptoms in 11 (69%) and with preced-
ing symptoms in one patient. Two patients died of noncar-
diac reasons (cerebral bleeding, thyroid C-cell carcinoma).
During follow-up, 37 patients (28%) developed significant
LV dilation, defined as end-diastolic volumes larger than
the mean value of normal end-diastolic volume (75 ml/m2)
plus two standard deviations (26 ml/m2); the normal value
was obtained from 18 persons without cardiac disease.
Figure 1 shows the cumulative survival curves; four deaths
occurred in the group without dilation, 12 deaths in the
group with dilation. Mortality in the group with LV
dilation (23.4%) was significantly higher (p 5 0.00018) than
it was in the group without dilation (5.8%).
Clinical characteristics, medication and laboratory find-
ings. Table 1 shows that nonsurvivors were older, that MI
size was larger and that percent narrowing of the infarct-
related coronary artery was greater. All other variables,
including laboratory tests (not shown), MI-related artery
and number of affected coronary arteries, were similar in
both groups. Perfusion of the MI-related artery tended to be
worse in nonsurvivors. At last visit (Table 2), pulmonary
wedge pressure, plasma creatinine, BUN and ANP were
significantly higher in nonsurvivors compared with survi-
vors. All other characteristics were similar in both groups,
including serum electrolytes (not shown).
Volumes and hemodynamics. Time course of LV end-
diastolic volume is shown in Figure 2A. End-diastolic (Fig.
2A) and end-systolic (not shown) volume progressively
increased in nonsurvivors significantly more than it did in
survivors. Ejection fraction (Fig. 2B) in nonsurvivors was
always lower than it was in survivors; stroke volume index
(Fig. 2C) normalized after four weeks but fell thereafter.
Wedge pressure was elevated in nonsurvivors at last visit
(Table 2).
ECG. Mean heart rate was higher in nonsurvivors than it
was in survivors at four days but was similar in both groups
during further observation (Fig. 3B). A clear sinus-wave
shaped curve was observed at maximum heart rate in
survivors at anytime (Fig. 3A). Maximal heart rate was
higher in nonsurvivors than it was in survivors at four days,
and the typical sinus curve was lost (Fig. 3A). In nonsurvi-
vors, maximum heart rate sharply increased at 0.5 years (Fig.
3A). Figure 2D shows that maximum QTc was elevated
after MI and remained increased in nonsurvivors while it
decreased 0.5 years after infarction in survivors. Dispersion
Table 1. Baseline Clinical Characteristics and Angiographic
Findings
Survivors
(n 5 118)
Nonsurvivors
(n 5 16) p Value
Gender (M/F) 113/5 14/2 NS
Age 55.3 6 0.8 61.1 6 1.8 0.0103
Thrombolytic therapy on
admission
50 (42.4%) 6 (37.5) NS
Characterization of
infarction:
Anterior 45 (38.1%) 5 (31.3%) NS
Lateral 10 (8.5%) 0
Inferior 59 (50%) 10 (62.5%) NS
Q-wave 61 (51.7) 9 (56.3) NS
Wedge pressure
(mm Hg)
10.4 6 0.5 15.0 6 1.7 ,0.05
Right atrial pressure
(mm Hg)
5.7 6 0.4 8.2 6 1.5 ,0.05
Ventriculographic infarct
size (%)
11.8 6 1.2 24.0 6 3.2 0.0431
Percent narrowing of
MI-related artery
74.7 6 3.0 81.5 6 6.8 ,0.0001
TIMI grade* of
MI-related artery
1.84 6 0.11 1.45 6 0.28 NS
Values are mean 6 SEM. *TIMI grade: “0” 5 no flow; “1” 5 minimal perfusion; “2”
5 partial perfusion; “3” 5 complete perfusion.
MI 5 myocardial infarction; TIMI 5 Thrombolysis In Myocardial Infarction.
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of QTc (Fig. 2E) decreased over time but was always
significantly higher in nonsurvivors than it was in survivors.
Lown classification (Fig. 2F) was similar in survivors and
nonsurvivors early after infarction but significantly increased
in nonsurvivors over time. There is a highly significant
positive correlation between LV end-diastolic volume and
QTc duration (r2 5 0.998, p 5 0.0030) or Lown score (r2 5
0.980, p , 0.0001), respectively. The SDNN in survivors
increased beyond four days and remained stable after
0.5 years following MI while it was reduced initially,
increased after four days but fell again until three years after
MI in nonsurvivors (not shown). The SDANN in survivors
was depressed four days after MI and showed a tendential
increase thereafter. The SDANN in nonsurvivors initially
was depressed but showed a significant increase until six
months after MI and remained stable thereafter (not
shown).
Multivariate analysis of predictors of death. The statis-
tical procedure selected discscore, maximal heart rate, cre-
atine, stroke volume index and pulmonary wedge pressure as
early predictors of death. Intermediate predictors of death
included parameters of cardiac electrical instability (QTc
dispersion, Lown score, maximal heart rate and QTc) and
end-systolic volume. Late predictors of sudden death were
end-systolic volume and maximum QTc duration.
DISCUSSION
A major result of this prospective study was that patients
who die in the chronic course after MI show progressive LV
dilation, dysfunction and electrical instability. Morphologic,
hemodynamic and electrical changes were closely inter-
related, and most deaths occurred suddenly. Association of
higher mortality with dilation is in accordance with a
Table 2. Clinical Characteristics, Interval Revascularization, Drug Therapy and Laboratory
Findings at Last Visit in Survivors and Nonsurvivors
Survivors
(n 5 118)
Nonsurvivors
(n 5 16)
p
Value
Clinical characteristics:
Hypertension 24 (20%) 2 (13%) NS
Diabetes 6 (5%) 1 (6%) NS
Current smoking 47 (40%) 6 (38%) NS
High cholesterol (.220 mg/dl)* 66 (56%) 10 (63%) NS
Recurrent infarction 14 (12%) 2 (13%) NS
New York Heart Association functional class:
I 66 (56%) 12 (75%) NS
II 37 (31%) 3 (19%) NS
III 0 1 (6%)
IV 0 0
Canadian Heart Association angina class:
I 83 (70%) 14 (88%) NS
II 18 (15%) 2 (12%) NS
III 0 0
IV 0 0
Pulmonary wedge pressure (mm Hg) 10.3 6 0.7 22.0 6 3.4 p , 0.05
Interval revascularization:
PTCA 7 (6%) 1 (6%) NS
Coronary bypass surgery 4 (3%) 1 (6%) NS
Drug therapy:
ACE inhibitors 19 (16%) 3 (19%) NS
Antiarrhythmic drugs 7 (6%) 1 (6%) NS
Warfarin 33 (28%) 6 (38%) NS
Acetylsalicylic acid 58 (49%) 7 (44%) NS
Beta-blockers 56 (48%) 4 (25%) NS
Calcium channel blockers 36 (31%) 3 (19%) NS
Digitalis 19 (16%) 3 (19%) NS
Diuretics 13 (11%) 2 (13%) NS
Nitrates 69 (58%) 5 (40%) NS
Laboratory findings:
Serum creatinine (mg/dl)† 1.05 6 0.18 1.66 6 1.07 p 5 0.0386
BUN (mg/dl)‡ 17.3 6 4.3 27.6 6 13.1 p 5 0.0035
Serum digoxin 1.6 6 0.2 1.4 6 0.2 NS
Plasma norepinephrine (pg/ml) 206 6 128 182 6 111 NS
Plasma renin (ng/ml/h) 4.6 6 10.5 5.2 6 4.5 NS
Plasma ANP (pg/ml) 51 6 32 129 6 34 p , 0.0001
Values are mean 6 SEM. *For conversion to pmol/l multiplication factor 5 0.02586; †for conversion to pmol/l multiplication
factor 5 88.4; ‡BUN, for conversion to mmol/l multiplication factor 5 0.357.
ACE 5 angiotensin-converting enzyme; ANP 5 atrial natriuretic peptide; BUN 5 blood urea nitrogen; PTCA 5
percutaneous transluminal coronary angioplasty.
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previous study that has shown that a single measurement of
LV volume is a strong predictor of prognosis (12). This
study suggests (in concert with previous data [13]) that this
single measurement is part of a progressive process. It
supports (along with observations of others [14]) the con-
cept that LV dilation after MI is both a compensatory
mechanism to restore stroke volume and a pathomechanism
for progressive dysfunction. The severity of circulatory
dysfunction is reflected by an increased plasma creatinine,
BUN and ANP at last visit. Heart rate abnormalities
associated with increased risk for sudden death were detect-
able early after MI. Later on (.4 weeks, #3 years),
pathological dispersion and duration of QTc interval and
Lown classification were identified as predictors of sudden
death by multivariate analysis. Thus, the present prospective
study demonstrates that gradual development of electrical
instability precedes sudden death in this population. Pa-
tients who died were also characterized early on by more
severe dysfunction. However, there was no significant rela-
tion between arrhythmias and ejection fraction. In contrast
and most importantly, LV volume correlates significantly
with Lown classification and QTc duration. The unique
quantitative relation between ventricular volume and char-
acteristics of ventricular arrhythmias suggests a mechanistic
interdependence. Mechanical variables in general were pre-
dictors of survival early after the infarct, while electric and
autonomic variables gained their predictive value later. The
clinical relevance of these observations needs to be tested
prospectively. In addition, the prevalence of ventricular
arrhythmias increases in parallel to symptoms of heart
failure (3,10). This study extends these observations to
asymptomatic patients with LV dysfunction and shows that
hemodynamic and structural (ventricular dilation and re-
modeling) abnormalities precede electrical abnormalities
and predict sudden death. However, a common prior cause
of both mechanical and electrical deterioration may not
entirely be excluded by these data. In addition, some
imbalance of drugs used in survivors and nonsurvivors,
although not statistically significant, may have influenced
the results.
Arrhythmias: potential mechanisms. The rate of sudden
death is very high in this study compared with others. The
reliability with regard to observations of sudden death has
been questioned recently (22). However, the close contact
with the patients and the observation that frequency and
complexity of ventricular arrhythmias increased gradually
suggests death by an arrhythmia. Plasma levels of electro-
lytes and the use of diuretics, digitalis and antiarrhythmic
drugs was similar, and we tried to prevent ischemic events at
the beginning and during the study. If ischemia was present,
coronary angiography was repeated and, if appropriate,
percutaneous transluminal coronary angioplasty or bypass
surgery was performed. There was no evidence for silent
ischemia in 24-h ECG recordings. Thus, systematic pre-
vention of ischemic events and exclusion of patients in
hemodynamic instability or heart failure immediately after
the infarct may have excluded patients at risk for events
other than sudden death. Elevated mean heart rate during
the first week after MI and elevated maximum heart rate at
0.5 years in nonsurvivors compared with survivors is com-
Figure 1. Cummulative survival curves for all patients in the study (solid line, n 5 134), for patients without left ventricular dilation (solid bar, n 5 97)
and for patients with left ventricular dilation (dotted line, n 5 37). Mortality was significantly (p 5 0.00018) higher in patients with left ventricular dilation
(32%) compared with patients who did not show left ventricular dilation (5%).
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Figure 2. (A) Shows that end-diastolic volume increased significantly and progressively and in nonsurvivors more than in it did in survivors. Left ventricular
ejection fraction was decreased in nonsurvivors (B). Stroke volume index increased in survivors while it was depressed in nonsurvivors except at four weeks
after infarction (C). (D) Shows that QTc duration decreased at and after 0.5 years after myocardial infarction in survivors but increased in nonsurvivors.
QTc dispersion was decreased in survivors versus nonsurvivors (E). Lown score in survivors remained unchanged over time (F). Lown score significantly
increased in nonsurvivors. Lown score 1 to 7 denotes: Lown grade 0; I; II; IIIa; IIIb; IVa; IVb. Values are mean 6 SEM. The horizontal dashed lines
indicate the upper (A,D,E) or lower (B,C) limit of normal for the respective value.
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patible with early autonomic disturbance, normalization
during subacute MI and recurrence of parasympathetic
withdrawal and sympathetic overactivity at 0.5 years after
MI. After this time interval, Lown score and maximum
QTc duration indicated electrical instability. Left ventricu-
lar remodeling after MI includes hypertrophy and fibrosis in
noninfarcted myocardial regions (23) and thinning and
elongation (i.e., expansion) of the infarcted region (23,24).
Hypertrophy is an independent risk factor for mortality and
sudden death (25). Elevation of LV filling pressure at rest or
during daily activities appears to contribute to global ven-
tricular dilation, and remodeling (26) and may predispose to
ventricular fibrillation by increasing dispersion of ventricular
repolarization (27). Fibrosis may decrease electrical coupling
and slow conduction velocity (27). The finding of the
present study, that LV volume—a composite marker of
remodeling—is significantly related to the development of
arrhythmias while ejection fraction is not, may indicate that
structural alterations are more closely related to the patho-
genesis of arrhythmias than functional parameters. From
this emerges the hypothesis that identification of LV
dilation and remodeling, in concert with markers of electri-
cal instability, should help identify patients at risk for
sudden death. One may speculate that arrhythmias and the
risk of sudden death may be reduced by therapeutic inter-
ventions aimed to attenuate LV remodeling. In fact, this
study is historical with regard to the therapy of patients with
LV dysfunction after MI. There is broad evidence that
beta-adrenergic blocking agents and angiotensin-converting
enzyme inhibitors may improve prognosis (28–30). The
data presented may give some evidence of their complex
mechanisms of action. In addition, the study suggests that
the rigid search for LV dilation, dysfunction, arrhythmias
and neurohumoral activation should be complementary in
Figure 3. Maximum and minimum heart rate (A) and mean heart rate in survivors and nonsurvivors (B).
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studying patients for more intense therapy and follow-up.
Progressive dilation should alert us to watch for life-
threatening arrhythmias to prevent sudden death.
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